This key provides the non-specialist with reference material to help recognise an invasive mosquito species and gives details on the morphology to help with verification.
The Protocol is targeted at the national public health reference laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
This expert opinion is intended to support national decision-making by summarising the considerations and concerns of some EU/EEA countries when they discussed whether to introduce the 4CMenB vaccine into their national immunisation programmes.
The aim of this document is to highlight measures that can effectively reduce the risk of importation and local transmission of pathogens transmitted by Ae. aegypti and Ae. albopictus. The main diseases of concern in this context are Zika, dengue, chikungunya and yellow fever.
This report describes many of the aspects that should be taken into account. It systematically covers the entire process from sample provision and sequencing to data analysis and collaboration with other organisations.
This protocol for harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter from human isolates aims to increase the quality and comparability of antimicrobial resistance data collected at the EU level from different Member States. It is primarily targeted to the National Public Health Reference Laboratories to guide the susceptibility testing needed for EU surveillance and the reporting to ECDC.
In May 2012 a collection of five strains of Haemophilus spp was sent to 28 participating reference laboratories in the IBD-labnet surveillance network for quality assurance testing. The laboratories were asked to characterise the five strains by performing standard laboratory protocols for the methods usually used by the laboratory for: species identification, biotyping and serotyping by serological methods and/or PCR.
The results of this EQA are published in the this report.
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national strategies and programmes in countries in Europe in order to reduce and prevent infections among people who inject drugs.
The content of this joint guidance was developed by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the support of a technical advisory group composed of policy makers, service providers, civil society representatives and preventative health experts from throughout the EU/EEA.